All lessons
Foundational Sciences · Pharmacology
Antidiabetic Drugs
A Step 1-focused survey of antidiabetic drug classes that ties each agent to its mechanism, signature toxicity, and classic board associations — spanning insulin, metformin, insulin secretagogues (sulfonylureas/meglitinides), TZDs, incretin-based therapies (GLP-1 agonists, DPP-4 inhibitors), SGLT2 inhibitors, α-glucosidase inhibitors, and pramlintide. Emphasizes the high-yield discriminators USMLE vignettes hinge on: which drugs cause hypoglycemia, lactic acidosis, euglycemic DKA, edema/CHF, genital candidiasis, and the medullary-thyroid-carcinoma contraindication.
15 min readHigh yield
Overview: Match Mechanism to Toxicity
Antidiabetic drugs lower glucose through a handful of distinct strategies: replace insulin, augment insulin secretion, improve insulin sensitivity, boost incretins, slow carbohydrate absorption, or dump glucose in the urine. For Step 1, do not memorize drugs in isolation — anchor each one to (1) its mechanism, (2) its highest-yield toxicity, and (3) any classic drug-specific association.
Three orientation points make the class tractable:
- Insulin, sulfonylureas, and meglitinides are the agents that cause hypoglycemia — they raise insulin regardless of the current glucose.
- Metformin is first-line for T2DM, does not cause hypoglycemia, and carries the signature risk of lactic acidosis.
- The incretin (GLP-1 / DPP-4) and SGLT2 inhibitor classes are newer, heavily tested, and are distinguished by weight loss / cardiorenal benefit and a small set of characteristic adverse effects.
Insulin — Types & Core Concepts
- Mechanism: binds the insulin receptor tyrosine kinase → recruits GLUT4 to muscle/adipose membranes (glucose uptake), stimulates glycogen/protein/fat synthesis, and drives K⁺ into cells.
- Rapid-acting — lispro, aspart, glulisine: taken with meals for postprandial spikes.
- Short-acting — regular insulin: the only insulin routinely given IV → drug of choice for DKA and for hyperkalemia (with glucose).
- Intermediate — NPH: basal coverage with a peak.
- Long-acting — glargine, degludec (essentially peakless), detemir (flat, modest peak): once-daily basal control.
- Indications: all of T1DM and DKA; advanced/insulin-deficient T2DM; gestational diabetes when diet fails.
- Toxicity: hypoglycemia (the big one), weight gain, lipodystrophy at injection sites, and can precipitate hypokalemia (intracellular K⁺ shift).
Non-Insulin Classes — MOA + Signature Toxicity
- Metformin (biguanide): ↓ hepatic gluconeogenesis (activates AMPK), ↑ peripheral insulin sensitivity. First-line T2DM. No hypoglycemia, weight neutral/loss. Toxicity: lactic acidosis (avoid in renal failure / hold around IV contrast), B12 deficiency, GI upset.
- Sulfonylureas (glyburide, glipizide, glimepiride — 2nd gen): close the β-cell K⁺ATP channel → depolarization → Ca²⁺ influx → insulin release (needs functional β cells). Toxicity: hypoglycemia, weight gain; 1st-gen chlorpropamide → disulfiram-like reaction + SIADH.
- Meglitinides (repaglinide, nateglinide): close the same K⁺ATP channel at a different site → postprandial insulin. Toxicity: hypoglycemia, weight gain.
- Thiazolidinediones (pioglitazone, rosiglitazone): PPAR-γ nuclear receptor agonists → ↑ insulin sensitivity, ↑ adiponectin. Toxicity: fluid retention/edema, weight gain, CHF exacerbation (contraindicated in heart failure), fractures; pioglitazone → bladder cancer risk.
- GLP-1 agonists (semaglutide, liraglutide, exenatide): ↑ glucose-dependent insulin, ↓ glucagon, delay gastric emptying, ↑ satiety → weight loss; ASCVD benefit. Toxicity: nausea/vomiting, pancreatitis; contraindicated with personal/family history of medullary thyroid carcinoma or MEN2.
- DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin): block DPP-4 → ↑ endogenous incretins (GLP-1/GIP). Weight neutral, generally mild; possible pancreatitis, arthralgias; saxagliptin/alogliptin carry a heart-failure hospitalization signal.
- SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin): block glucose reabsorption in the proximal (convoluted) tubule → glucosuria; strong cardiorenal protection (HF, CKD), weight loss. Toxicity: genital candidiasis / UTI, euglycemic DKA, volume depletion; rare Fournier gangrene (necrotizing perineal infection); canagliflozin — amputation/fracture signal.
- α-glucosidase inhibitors (acarbose, miglitol): inhibit intestinal brush-border enzymes → ↓ postprandial glucose. Toxicity: flatulence/diarrhea; no hypoglycemia alone.
- Pramlintide (amylin analog): ↓ glucagon, ↓ gastric emptying, ↑ satiety; used with insulin.
Drug-Class Comparison (Class → MOA → Use → Key Toxicity)
| Class (examples) | Mechanism | Key clinical use | Signature toxicity |
|---|---|---|---|
| Insulin (lispro, regular, NPH, glargine) | Receptor tyrosine kinase → GLUT4 uptake; shifts K⁺ into cells | T1DM, DKA (regular IV), hyperkalemia | Hypoglycemia, weight gain, lipodystrophy |
| Biguanide (metformin) | ↓ hepatic gluconeogenesis (AMPK); ↑ sensitivity | First-line T2DM | Lactic acidosis, B12 deficiency, GI |
| Sulfonylureas (glyburide, glipizide, glimepiride) | Close β-cell K⁺ATP channel → insulin release | T2DM (needs functional β cells) | Hypoglycemia, wt gain; chlorpropamide → disulfiram rxn/SIADH |
| Meglitinides (repaglinide, nateglinide) | Close K⁺ATP channel (different site) | Postprandial control | Hypoglycemia, weight gain |
| TZDs (pioglitazone, rosiglitazone) | PPAR-γ agonist → ↑ sensitivity, ↑ adiponectin | T2DM add-on | Edema/CHF, wt gain, fractures; pio → bladder ca |
| GLP-1 agonists (semaglutide, liraglutide, exenatide) | ↑ glucose-dependent insulin, ↓ glucagon, ↓ gastric emptying | T2DM + obesity (weight loss); ASCVD benefit | Nausea, pancreatitis; C/I in medullary thyroid ca/MEN2 |
| DPP-4 inhibitors (sitagliptin, saxagliptin) | Block DPP-4 → ↑ incretins (GLP-1/GIP) | T2DM (weight neutral) | Mild; ? pancreatitis, arthralgia; saxagliptin — HF hospitalization |
| SGLT2 inhibitors (empagliflozin, canagliflozin) | Block proximal-tubule glucose reabsorption → glucosuria | T2DM w/ HF/renal/CV benefit | Genital candidiasis/UTI, euglycemic DKA, hypovolemia; rare Fournier gangrene |
| α-glucosidase inhibitors (acarbose, miglitol) | Inhibit intestinal brush-border enzymes | Postprandial hyperglycemia | GI: flatulence, diarrhea |
| Amylin analog (pramlintide) | ↓ glucagon, ↓ gastric emptying | Adjunct to insulin | Hypoglycemia (with insulin), nausea |
Vignette → Drug (Toxicity Recognition)
- A 62-year-old with T2DM and CKD develops nausea, hyperventilation, and an anion-gap metabolic acidosis with elevated lactate the day after a contrast CT → Metformin (lactic acidosis; hold around contrast/renal impairment).
- A T2DM patient on a "-gliflozin" presents with nausea, abdominal pain, and ketoacidosis but glucose only ~180 mg/dL → SGLT2 inhibitor (euglycemic DKA).
- A woman on pioglitazone gains weight and develops bilateral leg edema, dyspnea, and JVD → TZD (fluid retention → CHF exacerbation).
- An elderly patient with renal impairment on glyburide is found confused and diaphoretic with glucose 38 mg/dL → Sulfonylurea hypoglycemia (prefer glipizide in renal disease).
- A patient started on a weekly injectable for T2DM/weight loss develops severe epigastric pain radiating to the back with ↑ lipase → GLP-1 agonist (pancreatitis); also screen for personal/family history of medullary thyroid carcinoma.
- A woman on an SGLT2 inhibitor develops recurrent vulvovaginal yeast infections → glucosuria-driven genital candidiasis.
Memory Hooks
Drug-name suffix → class (the standard, single most useful pattern):
- -gliflozin = SGLT2 inhibitor → "sugar FLOws out in urine"
- -gliptin = DPP-4 inhibitor
- -glitazone = TZD (PPAR-γ)
- -glutide / -natide ("-tide") = GLP-1 / incretin agents
"SGLT2 → Sugar Lost in the Toilet" → glucosuria → genital yeast/UTIs + euglycemic DKA.
pio-GLITAZONE — think "BIG BLADDER + swollen legs" → real associations of bladder cancer + edema/CHF.
MetforMIN — MIND the kidneys → lactic acidosis; hold around contrast.
High-Yield Exam Traps
- Cause hypoglycemia: insulin, sulfonylureas, meglitinides (and pramlintide with insulin). Do NOT cause hypoglycemia as monotherapy: metformin, TZDs, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors, acarbose.
- Weight effects: gain → insulin, sulfonylureas, meglitinides, TZDs. Loss → GLP-1 agonists, SGLT2 inhibitors, (metformin neutral/loss). Neutral → DPP-4 inhibitors.
- Acarbose-related hypoglycemia (only when combined with a secretagogue/insulin) must be treated with oral glucose/dextrose, NOT sucrose — acarbose blocks disaccharide breakdown.
- Renal disease: metformin contraindicated with significant renal impairment (classically eGFR <30); glyburide causes prolonged hypoglycemia in renal failure → prefer glipizide; SGLT2 inhibitors lose glucose-lowering efficacy at low GFR but remain renoprotective.
- Regular insulin is the insulin given IV for DKA/hyperkalemia; give it with glucose when treating hyperkalemia to avoid hypoglycemia.
Vignette → Drug (Indication & Associations)
- A 19-year-old with T1DM presents with Kussmaul breathing, fruity breath, glucose 520, ketones, and anion-gap acidosis → IV fluids + IV regular insulin + K⁺ repletion (DKA).
- An oliguric patient with peaked T waves and K⁺ 6.8 → insulin + glucose to shift K⁺ intracellularly (plus IV calcium to stabilize the myocardium).
- A newly diagnosed obese T2DM patient with normal renal function → start metformin as first-line.
- A T2DM patient with established atherosclerotic CVD who needs an add-on → favor a GLP-1 agonist or SGLT2 inhibitor; if heart failure or CKD predominates → favor an SGLT2 inhibitor (proven HF/renal benefit).
- Postprandial glucose spikes despite adequate basal (glargine) coverage → add rapid-acting insulin (lispro/aspart) with meals, or a meglitinide.
- An older patient on a first-generation sulfonylurea (chlorpropamide) who flushes and vomits after alcohol → disulfiram-like reaction; the same drug also classically causes SIADH.
Practice Pharmacology now
Board-style questions, spaced-repetition flashcards, and a Socratic AI tutor — free to start.